PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 18788725-1 2008 The liver-specific organic cation transport protein (OCT1; SLC22A1) transports several cationic drugs including the antidiabetic drug metformin and the anticancer agents oxaliplatin and imatinib. Oxaliplatin 170-181 solute carrier family 22 member 1 Homo sapiens 53-57 31344863-4 2019 Cellular oxaliplatin accumulation and DNA-adduct formation were decreased and related to OCT1-3 and ATP7A expression. Oxaliplatin 9-20 solute carrier family 22 member 1 Homo sapiens 89-93 29417972-5 2018 The aim of this study was to investigate the relevance of copper transporter 1 (CTR1) and organic cation transporters 1-3 (OCT1-3) for oxaliplatin uptake and resistance to the drug in sensitive and oxaliplatin-resistant ileocecal colorectal adenocarcinoma cells. Oxaliplatin 135-146 solute carrier family 22 member 1 Homo sapiens 90-121 29417972-5 2018 The aim of this study was to investigate the relevance of copper transporter 1 (CTR1) and organic cation transporters 1-3 (OCT1-3) for oxaliplatin uptake and resistance to the drug in sensitive and oxaliplatin-resistant ileocecal colorectal adenocarcinoma cells. Oxaliplatin 135-146 solute carrier family 22 member 1 Homo sapiens 123-129 29417972-5 2018 The aim of this study was to investigate the relevance of copper transporter 1 (CTR1) and organic cation transporters 1-3 (OCT1-3) for oxaliplatin uptake and resistance to the drug in sensitive and oxaliplatin-resistant ileocecal colorectal adenocarcinoma cells. Oxaliplatin 198-209 solute carrier family 22 member 1 Homo sapiens 90-121 29417972-5 2018 The aim of this study was to investigate the relevance of copper transporter 1 (CTR1) and organic cation transporters 1-3 (OCT1-3) for oxaliplatin uptake and resistance to the drug in sensitive and oxaliplatin-resistant ileocecal colorectal adenocarcinoma cells. Oxaliplatin 198-209 solute carrier family 22 member 1 Homo sapiens 123-129 29417972-7 2018 Pre- as well as co-incubation with the OCT1 inhibitor atropine led to a significant reduction in oxaliplatin accumulation in sensitive but not in resistant cells. Oxaliplatin 97-108 solute carrier family 22 member 1 Homo sapiens 39-43 29417972-12 2018 A fluorescent oxaliplatin derivative CFDA-oxPt co-localized with CTR1, OCT1 and OCT2 in sensitive cells, but only with CTR1 and OCT2 in the resistant cell line. Oxaliplatin 14-25 solute carrier family 22 member 1 Homo sapiens 71-75 29417972-15 2018 Uptake of oxaliplatin via OCT1 appears to take place in the sensitive but not in the resistant cell line underscoring the transporter relevance for oxaliplatin resistance. Oxaliplatin 10-21 solute carrier family 22 member 1 Homo sapiens 26-30 29417972-15 2018 Uptake of oxaliplatin via OCT1 appears to take place in the sensitive but not in the resistant cell line underscoring the transporter relevance for oxaliplatin resistance. Oxaliplatin 148-159 solute carrier family 22 member 1 Homo sapiens 26-30 26859833-3 2016 The intracellular distribution of oxaliplatin is mediated by organic cation transporters 1, 2 and 3 (OCT1, 2 and 3), copper transporter 1 (CTR1) and ATPase Cu2+ transporting beta polypeptide (ATP7B) and may modulate the efficacy of oxaliplatin-based chemotherapy. Oxaliplatin 34-45 solute carrier family 22 member 1 Homo sapiens 61-99 26859833-3 2016 The intracellular distribution of oxaliplatin is mediated by organic cation transporters 1, 2 and 3 (OCT1, 2 and 3), copper transporter 1 (CTR1) and ATPase Cu2+ transporting beta polypeptide (ATP7B) and may modulate the efficacy of oxaliplatin-based chemotherapy. Oxaliplatin 34-45 solute carrier family 22 member 1 Homo sapiens 101-114 20709029-4 2010 The cellular uptake of complex 2, like that of oxaliplatin, occurred mainly via organic cation transporters (OCT-1/2; ~32%) and copper transporter related proteins (Ctr1; ~24%), whereas that of chalcone 1 was dependent on endocytosis (~80%). Oxaliplatin 47-58 solute carrier family 22 member 1 Homo sapiens 109-116 18788725-1 2008 The liver-specific organic cation transport protein (OCT1; SLC22A1) transports several cationic drugs including the antidiabetic drug metformin and the anticancer agents oxaliplatin and imatinib. Oxaliplatin 170-181 solute carrier family 22 member 1 Homo sapiens 59-66 16914559-0 2006 Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). Oxaliplatin 14-25 solute carrier family 22 member 1 Homo sapiens 117-124 18030470-10 2008 In addition, the cellular accumulation of platinum and level of ATP7A mRNA may be factors affecting the cytotoxicity of cisplatin, while the cytotoxicity of oxaliplatin was suggested to be affected by the levels of ATP7A and hOCT1 mRNAs. Oxaliplatin 157-168 solute carrier family 22 member 1 Homo sapiens 225-230 16951202-3 2006 This study shows that the human organic cation transporters (OCT) 1 and 2 (SLC22A1 and SLC22A2) markedly increase oxaliplatin, but not cisplatin or carboplatin, accumulation and cytotoxicity in transfected cells, indicating that oxaliplatin is an excellent substrate of these transporters. Oxaliplatin 229-240 solute carrier family 22 member 1 Homo sapiens 32-73 16951202-3 2006 This study shows that the human organic cation transporters (OCT) 1 and 2 (SLC22A1 and SLC22A2) markedly increase oxaliplatin, but not cisplatin or carboplatin, accumulation and cytotoxicity in transfected cells, indicating that oxaliplatin is an excellent substrate of these transporters. Oxaliplatin 114-125 solute carrier family 22 member 1 Homo sapiens 32-73 16951202-3 2006 This study shows that the human organic cation transporters (OCT) 1 and 2 (SLC22A1 and SLC22A2) markedly increase oxaliplatin, but not cisplatin or carboplatin, accumulation and cytotoxicity in transfected cells, indicating that oxaliplatin is an excellent substrate of these transporters. Oxaliplatin 114-125 solute carrier family 22 member 1 Homo sapiens 75-82 16951202-3 2006 This study shows that the human organic cation transporters (OCT) 1 and 2 (SLC22A1 and SLC22A2) markedly increase oxaliplatin, but not cisplatin or carboplatin, accumulation and cytotoxicity in transfected cells, indicating that oxaliplatin is an excellent substrate of these transporters. Oxaliplatin 229-240 solute carrier family 22 member 1 Homo sapiens 75-82 16951202-6 2006 These results indicate that OCT1 and OCT2 are major determinants of the anticancer activity of oxaliplatin and may contribute to its antitumor specificity. Oxaliplatin 95-106 solute carrier family 22 member 1 Homo sapiens 28-32